Sorriso is a biopharmaceutical company advancing a pipeline of disease-modifying antibodies for the treatment of immune-mediated diseases, including Crohn’s disease and ulcerative colitis. The company's platform generates potent antibodies that can be delivered orally and are designed to maintain activity throughout the human intestine.